Brian Skotko is a Rare/Genetic physician affiliated with Harvard University. OpenAlex indexes 187 publications with 7,109 citations (h-index 40); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
185 Cambridge St Rm 2222
Boston, MA 021142790
Telephone
617-643-3196Registry record last updated 29 Aug 2012.
Clinical trials
- An Online Health Tool About Down Syndrome: Down Syndrome Clinic to You
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alnylam Pharmaceuticals Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
100%l-Thyroxine100%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2011–2026 per NIH RePORTER. The latest:
- Repurposing a Reverse Transcriptase Inhibitor To Target Retrotransposons and Prevent Alzheimer's Disease in People with Down Syndrome: A Two-Phase UG3/UH3 Clinical Drug Development Program
Brigham and Women'S Hospital
FY2026$1,478,201UG3AG101657 - Nicotinamide Adenine Dinucleotide Augmentation to Prevent or Reverse the Progression of Alzheimer's Disease in People with Down Syndrome
Brigham and Women'S Hospital
FY2025$801,359R01AG088141 - Effects of Hypoglossal Nerve Stimulation on Cognition & Language in Down Syndrome
Massachusetts Eye and Ear Infirmary
FY2024$694,646U01DC019279
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Assessment and Diagnosis of Down Syndrome Regression Disorder: International Expert Consensus
Frontiers in Neurology
2022 - Evaluation of Upper Airway Stimulation for Adolescents With Down Syndrome and Obstructive Sleep Apnea
JAMA Otolaryngology–Head & Neck Surgery
2022 - A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome
Journal of Neurodevelopmental Disorders
2022 - Unexplained regression in Down syndrome: Management of 51 patients in an international patient database
American Journal of Medical Genetics Part A
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”